1. Repurposing of nifedipine loaded in situ ophthalmic gel as a novel approach for glaucoma treatment.
- Author
-
El-Feky YA, Fares AR, Zayed G, El-Telbany RFA, Ahmed KA, and El-Telbany DFA
- Subjects
- Administration, Ophthalmic, Animals, Calcium Channel Blockers administration & dosage, Calcium Channel Blockers pharmacology, Chemistry, Pharmaceutical, Delayed-Action Preparations, Disease Models, Animal, Drug Liberation, Drug Repositioning, Gels, Hydrogen-Ion Concentration, Hypromellose Derivatives chemistry, Male, Nifedipine administration & dosage, Poloxamer chemistry, Rabbits, Temperature, Drug Delivery Systems, Glaucoma drug therapy, Intraocular Pressure drug effects, Nifedipine pharmacology
- Abstract
Glaucoma is a chronic eye disease characterized by elevated intraocular pressure (IOP) which causes severe complications to the eyes and may lead to vision loss. The effective treatment of such diseases motivated the search for novel and unique drugs and delivery systems. It has been reported that, nifedipine (NF) is effective in reducing the elevated IOP due to vasodilatation of eye vascular smooth muscles. NF loaded thermo-sensitive in situ gels were prepared by the cold method using poloxamer 407 (P407) and hydroxypropyl methyl cellulose (HPMC) polymers adopting Box-Behnken experimental design. All the prepared formulae were tested for homogeneity, clarity, pH, isotonicity, gelling capacity, rheological behavior, in vitro drug release and were tested in vivo on rabbits. The prepared in situ gels were homogenous, transparent, having a pH ranged from 5 to 5.5 and undergo sol-gel transition within few seconds physiological temperature. The in situ gels showed sustained in vitro release of NF where about 76% of the loaded drug was released over 12 h. NF loaded in situ gels showed a 45.83 ± 2.91% reduction in the IOP, with no sign of toxicity or irritation to the eye in rabbits. The current investigations clarified the efficiency of this novel and unique NF loaded in situ gel for the control of the IOP compared to the conventional ophthalmic dosage forms., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF